Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-03-24
2000-02-08
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 23, 514 25, 514 28, 514 32, 514 42, 514 56, 514 60, 514 62, 536 55, A61K 3170
Patent
active
060228660
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
This invention relates to the prevention of the narrowing (stenosis) of tubular walls of an animal after the tubular walls have been traumatized. In one embodiment, this invention relates to the prevention of arterial restenosis after balloon angioplasty.
DESCRIPTION OF THE PRIOR ART
Balloon angioplasty is a widely accepted method of opening blockages in the coronary arteries. The balloon catheter was introduced experimentally in the early 1960's and was first applied clinically in the late 1970's. It has since assumed a major therapeutic role in the treatment of single and multiple vessel coronary artery disease (Baumgartner, H. R., 1963, Z. Ges. Exp. Med., 137:227). However in some patients after successful treatment by balloon angioplasty, arterial restenosis occurs. This time however the narrowing of the inner diameter (ID) of the artery is caused by growth (proliferation) of endothelial cells in the areas of irritation caused by the balloon angioplasty. Thus reblockage occurs not by cholesterol build-up but by build up of endothelial cells on the inner wall of the artery reducing the inner diameter (ID) of the artery leading to an infarct. In man, the restenotic lesion consists almost entirely, though not exclusively of vascular smooth muscle cells (Glazier, J. J., Williams, M. G., Madden, S. and Rickards, A. F., 1990, J. Roy. Coll. Phys. Lond., 24:292). Their accumulation within the artery lumen is a result of cell migration and proliferation. These two events are almost certainly due to the coordinated interaction of a number of different cytokines likely released by early accumulation of macrophages at the site of original tissue injury. This narrowing of the inner diameter (ID) of tubular walls or proliferation of cells is not however restricted or limited to the coronary arteries. It can also occur post operatively causing restenosis in for example peripheral vascular systems.
A number of proposals have been made in the prior art to prevent restenosis.
U.S. Pat. No. 5,087,244 (Wolinsky et al.) purports to teach the use of a catheter having an inelastic balloon at one end thereof, where the balloon has minute perforations and contains a concentrated heparin solution which will be released through the perforations contacting an area of the artery after angioplasty to prevent restenosis.
U.S. Pat. No. 5,116,864 (Hathaway et al.) purports to teach the prevention of restenosis in peripheral or cardiac vascular systems after vascular recanalisation by systemic administration of photo activatable psoralen to give serum psoralen levels which inhibit smooth muscle cell growth.
U.S. Pat. No. 5,092,841 (Spears, J. R.) purports to teach the treatment of an arterial wall injured during angioplasty by delivering bio-protective material between the wall and the angioplasty catheter so that the bio-protective material is entrapped and permeates into the tissues and vessels of the arterial wall during opposition of the angioplasty catheter.
EP 356275-A (Petitou et al.) purports to teach the use of new o-acylated glycosamino-glycan derivatives in the inhibition of post-operative restenosis.
Berk., B. C. et al in the J. Am. Coll. Cardiol. dated 1991 Vol. 17 #6 Supplement B, pp 111B-117B purports to discuss the pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty.
WO 9209561 (Itoh et al.) purports to teach the use of new ACAT inhibiting amide derivatives in treatment of restenosis after percutaneous transluminal coronary angioplasty.
WO 9208472 (Scarborough et al.) purports to teach the use of platelet antiadhesive peptide(s) obtained from snake venom for the prevention of restenosis following angioplasty.
WO 9207852 (Bovy et al.) purports to teach the use of certain biphenylalkyl xanthine derivatives to prevent post-angioplasty restenosis.
WO 9205782 (Pill, J.) purports to teach the use of thromboxane-A2-receptor antagonists (I) in the preparation of medicaments for inhibition of proliferative developments in obstructive vascular disorders ie. ar
REFERENCES:
patent: 2583096 (1952-01-01), Hadidian et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4272522 (1981-06-01), Balazs
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4707354 (1987-11-01), Garlen et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4795741 (1989-01-01), Leshchiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4946870 (1990-08-01), Partain, III et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5032679 (1991-07-01), Brandley et al.
patent: 5116864 (1992-05-01), March et al.
patent: 5326757 (1994-07-01), Demopoulos
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellular Matrix. vol. III. New York: Academic Press, 1970. pp. 1241-1253.
Balazs EA, B and P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries. Polymers in Cosmetics 1984; 99: 65-72.
Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6):779-784.
Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
Chang N-S. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. Dissertation Abstracts International 1988; 49(2): 367-B.
Cravioto RO, Massieu GH, Izquierdo JJ. Effects of precipitates formed by insulin with hyaluronic acid and mucoid from vitreous humor in depressing blood-sugar levels. Science 1950; 111: 520-521.
Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. Arch. Immunol. Ther. Exp. (1980); 28 (3): 439-446.
Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration Acta Anaesthesiol.
Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis and Rheumatism (1973) Jan.-Feb.); 16 (1): 84-88.
Idson B. Polymers in skin cosmetics. Cosmetics & Toiletries 1988; 103: 63-68.
Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 736-738.
Kalbhen DA. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteo-arthrosis and its counteraction by a biological GAG-peptide complex ("Rumalon"). Zeitschrift fur Rheumatologie 1982; 41(5): 340-202-211.
Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence Nippon Rinsho (1968 Jan); 26(1): 89-95.
Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients.
McIlwraith W. Current concepts in equine degenerative joint disease. Journal of the American Veterinary Medical Association 1982; Feb. 1: 239-250.
Mizu
Asculai Samuel Simon
Falk Rudolf Edgar
Turley Eva Anne
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
MacMillan Keith D.
Sarkis Marcelo K.
LandOfFree
Use of hyaluronic acid and forms to prevent arterial restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hyaluronic acid and forms to prevent arterial restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hyaluronic acid and forms to prevent arterial restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1681605